Exelixis (NASDAQ: EXEL) reported Q1 EPS of $0.26, $0.13 better than the analyst estimate of $0.13. Revenue for the quarter came in at $356 million versus the consensus estimate of $374.75 million.

GUIDANCE:

Exelixis sees FY2022 revenue of $1.53-1.63 billion, versus the consensus of $1.64 billion.

Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:

Total revenues		$1.525 billion - $1.625 billion
Net product revenues		$1.325 billion - $1.425 billion
Cost of goods sold		5% - 6% of net product revenues
Research and development expenses (1)		$725 million - $775 million
Selling, general and administrative expenses (2)		$400 million - $450 million
Effective tax rate		20% - 22%

For earnings history and earnings-related data on Exelixis (EXEL) click here.